Exhibit 99.1 • The proposed confirmatory trial will be randomized and placebo-controlled, involving approximately 100 patients with a history of ≥2 surgeries per year, with a treatment option for the placebo arm at trial end. This trial design is intended to target a broader spectrum of RRP disease than other candidates currently in development. If INO-3107 receives full approval from the FDA, INOVIO believes the design of the confirmatory trial could also support expansion into global markets based on feed ...

PLYMOUTH MEETING, Pa., May 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments. "In the first quarter of 2024, we continued to deliver on our priorities for the year. Of utmost importance, we remain on track to submit our B ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of ...

PLYMOUTH MEETING, Pa., April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May: The Citizens JMP Life Sciences ConferenceDate: Tuesday, May 14, 2024Time: 11:30 AM ETPresenter: Dr. Jacqueline Shea, President & CEOFormat: Fireside Ch ...

PLYMOUTH MEETING, Pa., April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Mark Twyman - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Company Roy Buchanan - Citizens Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) (State or other jurisdiction of incorporation or organiza ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 14, 2024 12:40 PM ET Company Participants Jacque Shea - President and CEO Conference Call Participants Hartaj Singh - Oppenheimer Hartaj Singh Great, thank you operator for again, always making this so seamless and easy for us all. We have now Jacque Shea, the President and CEO of Inovio Company we've been covering for a while now. And we recently upgraded on the back of some really compelling data ...

Precancerous Anal Dysplasia: Phase 2 open-label trial n=24 3 or 4 dose regimen at Months 0, 1, 3 and Week 36 (optional) Final findings (6 months after start of treatment) Clearance of HPV 16/18+ lesions: 50% of patients The Spontaneous Rate is estimated to be less than 27% • VGX-3100: composed of plasmids encoding for HPV-16 and HPV-18 subtypes; E6 and E7 oncogenes • Open-label trial of VGX-3100 in 24 HIV-negative participants with HPV-16 and/or -18-positive anal HSIL • 50% (11/22 evaluable) of participants ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacque Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Mark Twyman - Chief Commercial Officer Conference Call Participants Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the Inovio Third Quarter 2023 Financia ...